Hims & Hers Health (NYSE:HIMS) Stock Price Up 7.1% - What's Next?

Key Points

• Hims & Hers shares rose 7.1% to approximately $31.42 in Tuesday trading, with volume well below the stock’s average session level.
• The company faces significant sentiment risks from multiple securities-fraud class-action solicitations linked to allegations involving an FTC complaint, alongside reported insider stock sales.
• Analysts maintain a consensus “Hold” rating with an average price target of $32.43. Although quarterly revenue increased 38.2% year over year to $753.2 million, the company missed EPS estimates and reported a net loss.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) were up 7.1% during trading on Tuesday . The company traded as high as $30.92 and last traded at $31.4240. 7,191,239 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 24,206,293 shares. The stock had previously closed at $29.35.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Investor attention around HIMS has increased substantially, with Zacks noting that the stock has become one of its most heavily searched names. Elevated attention can increase volatility but does not by itself change the company’s fundamentals. Zacks HIMS investor search article
• Negative Sentiment: Numerous law firms—including Rosen, Kaplan Fox, Hagens Berman, Robbins Geller, Faruqi & Faruqi, Bernstein Liebhard, SBS Law, Wolf Haldenstein and Glancy Prongay—are soliciting investors for a securities-fraud class action against Hims & Hers. The case covers investors who purchased shares from August 4, 2025 through July 29, 2026, with a November 2, 2026 deadline to seek lead-plaintiff status. The repeated notices increase reputational and potential legal-liability concerns, although they largely repeat the same procedural update. Rosen HIMS securities action notice
• Negative Sentiment: The litigation stems from allegations tied to a Federal Trade Commission complaint, which reportedly accuses Hims of serious business misconduct. If claims are substantiated, the company could face financial penalties, legal costs, management distraction and pressure on customer trust. Hagens Berman HIMS class action article
• Negative Sentiment: HIMS CFO-related insider selling was also reported, involving approximately $354,861 of stock. While one transaction is not necessarily a fundamental signal, insider selling can weigh on sentiment when combined with regulatory and litigation concerns. HIMS CFO stock sale article

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HIMS. Wall Street Zen raised shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research report on Tuesday, August 11th. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Truist Financial upped their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a report on Monday, August 24th. Finally, Canaccord Genuity Group increased their price target on Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $32.43.

Hims & Hers Health Price Performance

The company has a 50 day moving average price of $29.96 and a 200-day moving average price of $27.78. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The company has a market cap of $7.23 billion, a price-to-earnings ratio of -50.05 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter last year, the business earned $0.17 EPS. The firm's quarterly revenue was up 38.2% compared to the same quarter last year. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 14,027 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares of the company's stock, valued at $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah Autor sold 16,773 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the sale, the insider owned 48,961 shares of the company's stock, valued at $1,363,563.85. The trade was a 25.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 99,407 shares of company stock worth $2,855,023 in the last three months. 11.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bienville Capital Management LLC bought a new stake in Hims & Hers Health in the second quarter valued at approximately $27,242,000. Engineers Gate Manager LP acquired a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $232,000. Integrated Wealth Concepts LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $147,000. Baird Financial Group Inc. boosted its stake in shares of Hims & Hers Health by 384.6% in the 2nd quarter. Baird Financial Group Inc. now owns 65,575 shares of the company's stock valued at $2,273,000 after purchasing an additional 52,043 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $222,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.